Program
LPX-TI641
Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Multiple Sclerosis, led by LAPIX Therapeutics.
Furthest: phase 1, since Apr 28, 20233 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LAPIX Therapeutics | 32 open or running | phase 1since Apr 28, 2023 | Apr 28, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 28, 2023First study: phase 1 study in Autoimmune DiseasesFirst studyNCT05853835 · 72 enrolled · United States, Jordan
- Sep 26, 2024Phase 1 study in Arthritis, RheumatoidNCT06628206 · 48 enrolled · United States, Jordan
- May 13, 2025Phase 1 study in Dermatitis, AtopicNCT06982352 · 48 planned · United States, Jordan
Ahead
- Nov 15, 2026Primary completion: phase 1 study in Arthritis, RheumatoidNCT06628206
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06982352Dermatitis, Atopic · United States, Jordan | 1 | Recruiting | Jan 15, 2026 | 48 |
| NCT06628206Arthritis, Rheumatoid · United States, Jordan | 1 | Active, not recruiting | Nov 15, 2026 | 48 |
| NCT05853835Autoimmune Diseases · United States, Jordan | 1 | Completed | Aug 15, 2024 | 72 |
How it is read
Names in the registry
- “LPX-TI641”, 3 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
- Dermatitis, Atopic, 1 study
- Multiple Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.